AI-Assisted Mammography Interpretation: A Groundbreaking Clinical Trial

Strategic Insights -

A clinical trial at the Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, aims to assess the effectiveness of artificial intelligence (AI) in supporting radiologists in interpreting mammograms. Led by Jose Net, M.D., the study will involve hundreds of thousands of mammograms and evaluate whether AI can improve breast cancer screening while reducing unnecessary callbacks and anxiety for patients. The study is part of a $16 million award from the Patient-Centered Outcomes Research Institute (PCORI) and represents a pivotal step in the evaluation of AI's impact on breast cancer screening in the US.

Key Takeaways:

  • The PRISM Trial, a multi-institutional clinical trial, will evaluate whether AI can help radiologists interpret mammograms more accurately, improving breast cancer screening and reducing unnecessary callbacks and anxiety for patients.
  • The study will involve hundreds of thousands of mammograms interpreted at academic medical centers and breast imaging facilities in California, Florida, Massachusetts, Washington, and Wisconsin.
  • The AI support tool Transpara by ScreenPoint Medical will be used, with clinical workflow integration provided by the Aidoc aiOS platform.
  • Radiologists will remain in control of all diagnostic decisions, with mammograms being randomly assigned to be interpreted either by a radiologist alone or with assistance from the AI support tool.
  • The study will include focus groups and surveys to capture how patients and radiologists perceive and trust AI-assisted care.
  • The trial will inform future policy decisions, best practices in screening, and how to effectively integrate emerging technologies into patient care.
  • Six leading academic medical centers will participate in the trial, alongside the Sylvester Comprehensive Cancer Center.

Statistics:

  • $16 million: The amount awarded by the Patient-Centered Outcomes Research Institute (PCORI) to support the PRISM Trial.
  • 100,000s: Number of mammograms to be interpreted in the study, at academic medical centers and breast imaging facilities in five states.
  • 5: Number of states participating in the study, including California, Florida, Massachusetts, Washington, and Wisconsin.
  • 7: Number of academic medical centers participating in the trial, including UCLA Health, UC Davis Medical Center, Boston Medical Center, UC San Diego Health, University of Washington Medical Center, and University of Wisconsin Health.

Sources:

  • University of Miami Miller School of Medicine [Staf Writer | September 23, 2025]
  • Patient-Centered Outcomes Research Institute (PCORI) [n.d.]